PADCEV® with KEYTRUDA® Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that on December 15, 2023 the U.S. Food and Drug Administration (FDA) has…
ICON wins industry accolades from TIME Magazine, Forbes and Financial Times in second half of 2023
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial…
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has reached the next milestone in the establishment of mRNA vaccine manufacturing capacities in Africa with the inauguration of the Company’s site in…
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced topline results from the ADDRESS study…
Two Phase 3 Trials of Datopotamab Deruxtecan Plus DurvalumabInitiated in Patients Across Two Breast Cancer Subtypes
The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd)…
Decision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building “UK3” to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its decision today to invest in its Bio drug substance (DS) manufacturing facility “UK3” in the Ukima Plant (Kita-ku, Tokyo) of Chugai Pharma Manufacturing…
Chugai Venture Fund Starts Investment Activities in Drug Discovery Start-Ups to Accelerate Innovation
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that its corporate venture capital (CVC) subsidiary in the U.S.A., “Chugai Venture Fund, LLC” (CVF) finalized establishment of a $200M venture fund based in…
GSK enters exclusive license agreement with Hansoh for HS-20093
GSK plc (LSE/NYSE: GSK) and Hansoh Pharma (HKEX: 03692), a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders, today announced…
Aetna Better Health® of Illinois and Mae Health announce partnership to give members access to local doulas for pregnancy and postpartum health support
Aetna Better Health® of Illinois announced a new partnership with digital health platform Mae Health (“Mae”) to support the maternal health needs of its underserved pregnant and postpartum members in Cook and Kane…
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel,…
FDA grants priority review to Xolair for children and adults with food allergies based on positive National Institutes of Health phase III study results
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab)…
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares (“Shares”) of common stock of POINT…